The deal comes at a time when the Donald Trump administration is progressively disincentivising foreign pharma manufacturers, especially makers of non-generics and those shopping in drugs from other manufacturing hubs
To fuel its global ambitions, Sun Pharmaceutical Industries will acquire New Jersey-based Organon & Co in an all-cash deal that values the U.S. company at $11.75 billion.
Sun Pharmaceutical Industries Ltd. agreed to acquire New York-listed women’s health-care company Organon & Co., in what is likely to be one of the biggest India outbound deals in years.
